Structure Based Drug Design starts with Gene to Structure Services
Emerald BioStructures has developed a highly automated gene-to-structure pipeline. By industrializing the entire process, Emerald is the only CRO capable of processing large sets of multiple protein targets, or many variants of the same protein target in parallel for structure-guided drug design. Our pipeline allows us the unique ability to crystallize traditionally difficult targets, including membrane proteins, protein-protein complexes, and protein-nucleic acid complexes.
Emerald BioStructures provides multi-target, gene-to-structure research partnerships with biotechs, pharmaceutical companies, and research organizations within the government and academia. Our high-throughput X-ray crystallography expertise allows us to provide valuable structural insights to multi-target drug discovery pipelines. Emerald employs X-ray crystallography, biochemistry, robotics, and informatics to identify multiple drug targets.
Emerald BioSystems offers a full spectrum of technologies and services from establishing multi-target pipelines, ligand discovery screening, as well as some medicinal chemistry. Our methods are highly productive and allow our collaborators to rapidly discover numerous leads on active compounds as well as deliver active compounds.
Emerald has the capacity to determine the structure of molecules that have activity in their assay and provide insights may ultimately accelerate the path of drug discovery, and perhaps lead to highly effective, innovative therapeutics.
Emerald uses its high-throughput capabilities to crystallize targets, screen them using our proprietary Fragments of Life™ ligand library, test for biological assays, and determine the structures of active bound molecules. Emerald’s Gene To Structure program helps mitigate some of the risks of drug discovery by providing a targeted approach to structure guided drug discovery.